SEC Comment Letter for TuHURA Biosciences, (HURA) — Apr 24, 2019
TuHURA Biosciences, Inc./NV (HURA) (CIK 0001498382)
Date: April 24, 2019 · CIK: 0001498382 · Accession: 0000000000-19-007521
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-230929
Letter
April 24, 2019 Saiid Zarrabian President and Chief Executive Officer DelMar Pharmaceuticals, Inc. Suite 720-999 West Broadway Vancouver, BC, Canada V5Z 1K5 Re:DelMar Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed April 18, 2019 File No. 333-230929 Dear Mr. Zarrabian: We have limited our review of your registration statement to those issues we have addressed in our comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments. Registration Statement on Form S-1 filed on April 18, 2019 Cover page 1.We note your disclosure that the rights offering will expire on or about a certain date, and that you may extend the rights offering for additional periods in your sole discretion. Please revise your disclosure to provide an expiration date for the rights offering that is not indefinite. Refer to Item 501(b)(8)(iii) of Regulation S-K. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameSaiid Zarrabian Comapany NameDelMar Pharmaceuticals, Inc. April 24, 2019 Page 2 FirstName LastName Saiid Zarrabian DelMar Pharmaceuticals, Inc. April 24, 2019 Page 2
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Christine Westbrook at 202-551-5019 or Joe McCann at 202-551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Steven M. Skolnick, Esq.
Show Raw Text
April 24, 2019
Saiid Zarrabian
President and Chief Executive Officer
DelMar Pharmaceuticals, Inc.
Suite 720-999 West Broadway
Vancouver, BC, Canada V5Z 1K5
Re:DelMar Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed April 18, 2019
File No. 333-230929
Dear Mr. Zarrabian:
We have limited our review of your registration statement to those issues we have
addressed in our comment. In our comment, we may ask you to provide us with information so
we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to the comment, we may have additional comments.
Registration Statement on Form S-1 filed on April 18, 2019
Cover page
1.We note your disclosure that the rights offering will expire on or about a certain date, and
that you may extend the rights offering for additional periods in your sole discretion.
Please revise your disclosure to provide an expiration date for the rights offering that is
not indefinite. Refer to Item 501(b)(8)(iii) of Regulation S-K.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
FirstName LastNameSaiid Zarrabian
Comapany NameDelMar Pharmaceuticals, Inc.
April 24, 2019 Page 2
FirstName LastName
Saiid Zarrabian
DelMar Pharmaceuticals, Inc.
April 24, 2019
Page 2
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Christine Westbrook at 202-551-5019 or Joe McCann at 202-551-6262
with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Steven M. Skolnick, Esq.